Shire announces FDA approval of Vyvanse Capsules CII for ADHD in adolescents

Shire announces FDA approval of Vyvanse Capsules CII for ADHD in adolescents
Shire plc, the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the prescription medication Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents ages 13 to 17. The approval is based on study data demonstrating that Vyvanse improved ADHD symptoms ...

Read more on

Read more ...